Literature DB >> 17018549

Therapeutic approaches to Alzheimer's disease.

Hans-Wolfgang Klafki1, Matthias Staufenbiel, Johannes Kornhuber, Jens Wiltfang.   

Abstract

Alzheimer's disease is an age-related progressive neurodegenerative disorder with an enormous unmet medical need. It is the most common form of dementia affecting approximately 5% of adults over 65 years. In view of our ageing society the number of patients, as well as the economical and social impact, is expected to grow dramatically in the future. Currently available medications appear to be able to produce moderate symptomatic benefits but not to stop disease progression. The search for novel therapeutic approaches targeting the presumed underlying pathogenic mechanisms has been a major focus of research and it is expected that novel medications with disease-modifying properties will emerge from these efforts in the future. In this review, currently available drugs as well as novel therapeutic strategies, in particular those targeting amyloid and tau pathologies, are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17018549     DOI: 10.1093/brain/awl280

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  77 in total

Review 1.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

2.  Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregation inhibitors.

Authors:  Tarek Mohamed; Xiaobei Zhao; Lila K Habib; Jerry Yang; Praveen P N Rao
Journal:  Bioorg Med Chem       Date:  2011-03-01       Impact factor: 3.641

Review 3.  Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy.

Authors:  Eva Kontsekova; Natalia Ivanovova; Martina Handzusova; Michal Novak
Journal:  Cell Mol Neurobiol       Date:  2009-02-13       Impact factor: 5.046

4.  Amyloid fibril-like structure underlies the aggregate structure across the pH range for beta-lactoglobulin.

Authors:  Mark R H Krebs; Glyn L Devlin; Athene M Donald
Journal:  Biophys J       Date:  2009-06-17       Impact factor: 4.033

5.  Structure-activity relationships for a series of compounds that inhibit aggregation of the Alzheimer's peptide, Aβ42.

Authors:  Angela F McKoy; Jermont Chen; Trudi Schupbach; Michael H Hecht
Journal:  Chem Biol Drug Des       Date:  2014-05-21       Impact factor: 2.817

6.  Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study.

Authors:  Thomas Polak; Martin J Herrmann; Laura D Müller; Julia B M Zeller; Andrea Katzorke; Matthias Fischer; Fabian Spielmann; Erik Weinmann; Leif Hommers; Martin Lauer; Andreas J Fallgatter; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

Review 7.  Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders.

Authors:  Sandeep Kumar Singh; Saurabh Srivastav; Rudolph J Castellani; Germán Plascencia-Villa; George Perry
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 8.  Neurochemical dementia diagnostics: assays in CSF and blood.

Authors:  Piotr Lewczuk; Joachim Hornegger; Rüdiger Zimmermann; Markus Otto; Jens Wiltfang; Johannes Kornhuber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

9.  Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein.

Authors:  Katerina E Paleologou; Adrian W Schmid; Carla C Rospigliosi; Hai-Young Kim; Gonzalo R Lamberto; Ross A Fredenburg; Peter T Lansbury; Claudio O Fernandez; David Eliezer; Markus Zweckstetter; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2008-03-14       Impact factor: 5.157

10.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.